Sickle Cell Disease Clinical Trial
Official title:
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
The primary objectives of this prospective, observational study are (1) to describe the
long-term cellular, molecular, and clinical effects of hydroxyurea therapy in sickle cell
disease, and (2) to perform hydroxyurea pharmacokinetics studies.
This study will follow sickle cell patients being treated with hydroxyurea for a long period
of time to evaluate the long-term cellular and molecular effects of the drug on the patients'
body. This study will consist of two patient groups. One group will be made up of patients
who have received hydroxyurea therapy before entering the study. The second group will be
made up of patients who have not received hydroxyurea before study entry.
Many years of study have documented the severe effects of sickle cell disease. Some of these
effects include hemolysis (the break down of red blood cells), blockages in the blood
vessels, and damage to the organs systems of the body. Hydroxyurea, which is given by mouth,
is used to effectively prevent blockages in the blood vessels of patients with sickle cell
disease. The hydroxyurea dosage varies and the responses of the body to this drug are not
well understood.
This study will follow sickle cell patients being treated with hydroxyurea for a long period
of time to evaluate the long-term cellular and molecular effects of the drug on the patients'
body. This study will consist of two patient groups. One group will be made up of patients
who have received hydroxyurea therapy before entering the study (Old Cohort). The second
group will be made up of patients who have not received hydroxyurea before study entry (New
Cohort).
This is not a therapeutic drug trial. Subjects for this study will receive hydroxyurea
therapy for accepted clinical indications, and will be treated per best clinical management
using treatment algorithms established at St. Jude Children's Research Hospital and other
pediatric sickle cell programs across the United States. Hydroxyurea therapy data (such as
dosing and duration of therapy) will not be dictated by this study, but will be collected to
correlate with long-term outcomes. Hydroxyurea dose escalation to a stable MTD will occur
according to published guidelines.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02567682 -
Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A |